<DOC>
	<DOCNO>NCT02659384</DOCNO>
	<brief_summary>This randomized phase II study , aim evaluate efficacy ( progression free survival 6 month ) safety 5 different treatment involve atezolizumab , bevacizumab and/or acetylsalicylic acid advanced recurrent platinum-resistant ovarian cancer patient order select optimal treatment development Phase III .</brief_summary>
	<brief_title>Anti-programmed Cell Death-1 Ligand 1 ( aPDL-1 ) Antibody Atezolizumab , Bevacizumab Acetylsalicylic Acid Recurrent Platinum Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Recurrent , histologically proven , platinumresistant , epithelial ovarian , fallopian tube primary peritoneal cancer advance metastatic stage . Histological diagnosis image guide biopsy , laparoscopy laparotomy . Tumors diagnose cytology borderline tumor exclude . At least one lesion accessible biopsy without put patient risk WHO PS : 02 patient receive two previous line therapy . WHO PS : 01 patient receive &gt; 2 previous line therapy Prior chemotherapy bevacizumab : Any number platinumbased chemotherapy line allow maximum 2 previous nonplatinum contain line Prior treatment bevacizumab target agent Vascular Endothelial Growth Factor ( VEGF ) VEGF receptor allow , least 18 week must elapse since last administration Eligible patient ≤ 2 previous treatment line must previously expose bevacizumab target agent VEGF VEGF receptor Patients may prior therapy provide follow condition meet : Radiation therapy : washout period 14 day prior first study treatment ; exception : single fraction radiotherapy indication pain control Systemic antitumor therapy : washout period 21 day prior first study treatment Recovery toxic effect prior therapy ≤ Grade 1 per National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE v4.03 ) except fatigue alopecia . Exclusion criterion : Age &lt; 18 year Life expectancy &lt; 12 week No adequate hematologic end organ function Use acetylsalicylic acid , NSAIDs COX2 inhibitor stop baseline whole duration study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>